Clinical Outcomes after Treatment of Periodontal Intrabony Defects with Nanocrystalline Hydroxyapatite (Ostim) or Enamel Matrix Derivatives (Emdogain): A Randomized Controlled Clinical Trial
Figure 3
Distribution (%) of defect types as assessed during surgical intervention. NHA: nanocrystalline hydroxyapatite; EMD: enamel matrix derivate.